Work

Inhibition of the mutated c-KIT kinase in AML1-ETO–positive leukemia cells restores sensitivity to PARP inhibitor

Year: 2019

Type: article

Abstract: Key Points c-KIT activating mutations cause resistance to PARP inhibitor in AML1-ETO–positive leukemias. c-KIT inhibitor avapritinib downregulates BRCA1/2 and DNA-PK catalytic subunit to restore the sensitivity to PARP inhibitor.

Source: Blood Advances

DOI: 10.1182/bloodadvances.2019000756

Authors: Margaret Nieborowska-Skorska, Elisabeth M. Paietta, Ross L. Levine, Hugo F. Fernandez, Martin S. Tallman, Mark R. Litzow, Tomasz Skorski

Institutions: Temple University, Albert Einstein College of Medicine, Montefiore Medical Center, Memorial Sloan Kettering Cancer Center, Memorial Healthcare System, Mayo Clinic

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,800

Funders: Leukemia and Lymphoma Society, National Institutes of Health, National Cancer Institute

Awards: ECOG-ACRIN Network Group Operations Center, G270241475, Network Lead Academic Participating Site: Memorial Sloan Kettering Cancer Center, G5417201949, G6345179729, G9000134339, Cancer Center Support Grant

OpenAlex ID: W2993091173

FWCI: 0.725

Cites: 22

Cited by: 20

Related to: 10